These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35632467)

  • 21. Humoral and Cellular Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients with Multiple Sclerosis: An Israeli Multi-Center Experience Following 3 Vaccine Doses.
    Milo R; Staun-Ram E; Karussis D; Karni A; Hellmann MA; Bar-Haim E; Miller A;
    Front Immunol; 2022; 13():868915. PubMed ID: 35432335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 May; 28(5):701-709. PubMed ID: 34547457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Humoral and Cellular Response and Associated Variables Nine Months following BNT162b2 Vaccination in Healthcare Workers.
    Syrimi N; Sourri F; Giannakopoulou MC; Karamanis D; Pantousas A; Georgota P; Rokka E; Vladeni Z; Tsiantoula E; Soukara E; Lavda N; Gkaragkanis D; Zisaki A; Vakalidis P; Goula V; Loupou E; Palaiodimos L; Hatzigeorgiou D
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination.
    Gonzalez-Perez M; Montes-Casado M; Conde P; Cervera I; Baranda J; Berges-Buxeda MJ; Perez-Olmeda M; Sanchez-Tarjuelo R; Utrero-Rico A; Lozano-Ojalvo D; Torre D; Schwarz M; Guccione E; Camara C; Llópez-Carratalá MR; Gonzalez-Parra E; Portoles P; Ortiz A; Portoles J; Ochando J
    Front Immunol; 2022; 13():845882. PubMed ID: 35401504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody response after two doses of the BNT162b2 vaccine among healthcare workers of a Greek Covid 19 referral hospital: A prospective cohort study.
    Tychala A; Sidiropoulou E; Dionysopoulou S; Gkeka I; Meletis G; Athanasiadis A; Boura-Theodorou A; Chantzi C; Koutri M; Makedou K; Skoura L
    Heliyon; 2022 May; 8(5):e09438. PubMed ID: 35600436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell responses to vaccination with BNT162b2 and mRNA-1273 6 months after second dose.
    Markewitz R; Pauli D; Dargvainiene J; Steinhagen K; Engel S; Herbst V; Zapf D; Krüger C; Sharifzadeh S; Schomburg B; Leypoldt F; Rupp J; Görg S; Junker R; Wandinger KP
    Clin Microbiol Infect; 2022 Jul; 28(7):1024.e1-1024.e6. PubMed ID: 35259531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced humoral response 3 months following BNT162b2 vaccination in SARS-CoV-2 uninfected residents of long-term care facilities.
    Trigueros M; Pradenas E; Palacín D; Muñoz-López F; Ávila-Nieto C; Trinité B; Bonet-Simó JM; Isnard M; Moreno N; Marfil S; Rovirosa C; Puig T; Grau E; Chamorro A; Martinez A; Toledo R; Font M; Ara J; Carrillo J; Mateu L; Blanco J; Clotet B; Prat N; Massanella M;
    Age Ageing; 2022 May; 51(5):. PubMed ID: 35595256
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy.
    Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL
    Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibody Titer Kinetics and SARS-CoV-2 Infections Six Months after Administration with the BNT162b2 Vaccine.
    Ferrari D; Clementi N; Criscuolo E; Ambrosi A; Corea F; Di Resta C; Tomaiuolo R; Mancini N; Locatelli M; Plebani M; Banfi G
    Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.
    Demirbakan H; Koçer I; Erdoğan M; Bayram A
    Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
    Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
    Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Humoral Response After a Second Dose of SARS-CoV-2 mRNA Vaccine in Japanese Kidney Transplant Recipients.
    Ohki Y; Kawabe M; Yamamoto I; Katsumata H; Nakada Y; Kobayashi A; Urabe F; Miki J; Yamada H; Kimura T; Matsuo N; Tanno Y; Horino T; Ohkido I; Yamamoto H; Yokoo T
    Front Microbiol; 2022; 13():922042. PubMed ID: 35756063
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
    Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection.
    Schmidt KG; Harrer EG; Tascilar K; Kübel S; El Kenz B; Hartmann F; Simon D; Schett G; Nganou-Makamdop K; Harrer T
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamics of Antibody Response to BNT162b2 mRNA COVID-19 Vaccine: A 7-Month Follow-Up Study.
    Olariu TR; Ursoniu S; Marincu I; Lupu MA
    Medicina (Kaunas); 2021 Dec; 57(12):. PubMed ID: 34946275
    [No Abstract]   [Full Text] [Related]  

  • 37. SARS-CoV-2 Humoral and Cellular Immune Responses of Patients With HIV After Vaccination With BNT162b2 mRNA COVID-19 Vaccine in the Tel-Aviv Medical Center.
    Tau L; Turner D; Adler A; Marom R; Ahsanov S; Matus N; Levi I; Gerber G; Lev S; Ziv-Baran T; Hagin D; Freund T; Grupper A; Halperin T
    Open Forum Infect Dis; 2022 Apr; 9(4):ofac089. PubMed ID: 35355894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody Responses to BNT162b2 Vaccination in Japan: Monitoring Vaccine Efficacy by Measuring IgG Antibodies against the Receptor-Binding Domain of SARS-CoV-2.
    Fujigaki H; Yamamoto Y; Koseki T; Banno S; Ando T; Ito H; Fujita T; Naruse H; Hata T; Moriyama S; Takahashi Y; Suzuki T; Murakami T; Yoshida Y; Yagura Y; Oyamada T; Takemura M; Kondo M; Iwata M; Saito K
    Microbiol Spectr; 2022 Feb; 10(1):e0118121. PubMed ID: 35044205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired Functional T-Cell Response to SARS-CoV-2 After Two Doses of BNT162b2 mRNA Vaccine in Older People.
    Demaret J; Corroyer-Simovic B; Alidjinou EK; Goffard A; Trauet J; Miczek S; Vuotto F; Dendooven A; Huvent-Grelle D; Podvin J; Dreuil D; Faure K; Deplanque D; Bocket L; Duhamel A; Labreuche J; Sobaszek A; Hisbergues M; Puisieux F; Labalette M; Lefèvre G
    Front Immunol; 2021; 12():778679. PubMed ID: 34868051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination.
    Puro V; Castilletti C; Agrati C; Goletti D; Leone S; Agresta A; Cimini E; Tartaglia E; Casetti R; Colavita F; Meschi S; Matusali G; Lapa D; Najafi Fard S; Aiello A; Farrone C; Gallì P; Capobianchi MR; Ippolito G; On Behalf Of The Inmi Covid-Vaccine Study Group
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34201065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.